Skip to main content
. 2013 Nov 7;306(1):G72–G80. doi: 10.1152/ajpgi.00178.2013

Fig. 1.

Fig. 1.

Cholangiocyte proliferation, vascular endothelial growth factor-A (VEGF-A) production, and ERK activation after common bile duct ligation (CBDL) in the presence or absence of receptor tyrosine kinase (RTK) inhibition with sorafenib. Left: representative images of hepatic immunohistochemistry for CK-19 (cholangiocyte marker), PCNA (cell proliferation marker), ERK phosphorylation (p-ERK, Thr202/Tyr204), and VEGF-A production after CBDL. Arrows indicate bile ducts. Right: graphical summaries of mRNA levels for CK-19 and PCNA, and quantitation of immunohistochemical staining for p-ERK and VEGF-A. Values are expressed as means ± SE (n = 8 animals for each group). *P < 0.05 compared with sham. ‡P < 0.05 compared with CBDL.